TC
RNAM

Torno Capital’s Avidity Biosciences RNAM Stock Holding History

Torno Capital’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,000
Closed -$262K – 156
2024
Q4 		$262K Sell
9,000
-7,092
-44% -$296K 0.02% 110
2024
Q3 		$739K Buy
+16,092
New +$698K 0.11% 128

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Torno Capital's RNAM Position: Q1 2025 in Review

Torno Capital sold out of Avidity Biosciences (RNAM) in Q1 2025, closing a stake of 9,000 shares — an estimated $262K sold.

Torno Capital first reported a position in RNAM in Q3 2024 and held it in 2 quarters. The position peaked at $739K in Q3 2024. 220 funds tracked by Wall St. Rank hold RNAM as of Q1 2025.

  • Torno Capital reported no remaining Avidity Biosciences position as of Q1 2025 after selling out during the quarter.
  • Torno Capital sold 9,000 Avidity Biosciences shares in Q1 2025, an estimated $262K.
  • Torno Capital first reported a position in Avidity Biosciences in Q3 2024 and held it in 2 quarters.
  • Torno Capital's Avidity Biosciences position peaked at $739K in Q3 2024.
  • 220 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2025.

Based on Torno Capital's 13F filing for Q1 2025, filed 14 May 2025.